{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:09:23Z","timestamp":1790140163108,"version":"4.0.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamainternmed.2018.3034","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T12:31:37Z","timestamp":1534163497000},"page":"1190","source":"Crossref","is-referenced-by-count":144,"title":["Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes"],"prefix":"10.1001","volume":"178","author":[{"given":"Hsien-Yen","family":"Chang","sequence":"first","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Massachusetts Medical School, Worcester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mansour","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheriza","family":"Baksh","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Division of General Internal Medicine, Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"ioi180048r3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13300-015-0117-z","article-title":"Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: controlled trial.","volume":"6","author":"Fulcher","year":"2015","journal-title":"Diabetes Ther"},{"issue":"1","key":"ioi180048r4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/dom.12589","article-title":"Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.","volume":"18","author":"Fulcher","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"ioi180048r5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"ioi180048r6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi180048r7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/HPC.0000000000000125","article-title":"Update on SGLT2 inhibitors\u2014new data released at the American Diabetes Association.","volume":"16","author":"Lee","year":"2017","journal-title":"Crit Pathw Cardiol"},{"key":"ioi180048r8","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose absorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"issue":"3","key":"ioi180048r9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.amjmed.2016.10.016","article-title":"Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients.","volume":"130","author":"Chang","year":"2017","journal-title":"Am J Med"},{"issue":"3","key":"ioi180048r10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0895-4356(98)00161-9","article-title":"The use of automated data to identify complications and comorbidities of diabetes: a validation study.","volume":"52","author":"Newton","year":"1999","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"ioi180048r11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/1358863X14559589","article-title":"Development of administrative data algorithms to identify patients with critical limb ischemia.","volume":"19","author":"Bekwelem","year":"2014","journal-title":"Vasc Med"},{"issue":"4","key":"ioi180048r12","first-page":"213","article-title":"Predicting costs with Diabetes Complications Severity Index in claims data.","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"issue":"11","key":"ioi180048r13","first-page":"721","article-title":"Validating the adapted Diabetes Complications Severity Index in claims data.","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"issue":"7","key":"ioi180048r14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1\u2013based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ioi180048r15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/pds.v24.6","article-title":"Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.","volume":"24","author":"Chang","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"ioi180048r16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.2337\/dc15-0563","article-title":"Use of an a-glucosidase inhibitor and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based cohort study.","volume":"38","author":"Tseng","year":"2015","journal-title":"Diabetes Care"},{"issue":"9","key":"ioi180048r17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.7326\/M15-0308","article-title":"Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus.","volume":"163","author":"Ou","year":"2015","journal-title":"Ann Intern Med"},{"key":"ioi180048r18","doi-asserted-by":"publisher","first-page":"h1585","DOI":"10.1136\/bmj.h1585","article-title":"Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.","volume":"350","author":"Chang","year":"2015","journal-title":"BMJ"},{"issue":"21","key":"ioi180048r19","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1002\/cncr.30181","article-title":"Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.","volume":"122","author":"Casadaban","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"ioi180048r20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research.","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods"},{"issue":"3","key":"ioi180048r21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/aje\/kwj047","article-title":"Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.","volume":"163","author":"Kurth","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"3","key":"ioi180048r22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"ioi180048r23","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model.","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"ioi180048r24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals.","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"issue":"9","key":"ioi180048r27","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"ioi180048r28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/dom.2018.20.issue-3","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study.","volume":"20","author":"Yuan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"ioi180048r29","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1210\/jc.2016-3717","article-title":"Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease.","volume":"102","author":"Hsu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ioi180048r1","volume-title":"National Diabetes Statistics Report, 2017","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"ioi180048r2","unstructured":"US Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM558427.pdf. Updated May 16, 2017. Accessed October 17, 2017."},{"key":"ioi180048r25","unstructured":"European Medicines Agency. Pharmacovigilence Risk Assessment Committee (PRAC): PRAC assessment report. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors_Canagliflozin_20\/European_Commission_final_decision\/WC500227102.pdf. Published February 9, 2017. Accessed October 23, 2017."},{"key":"ioi180048r26","unstructured":"US Food and Drug Administration. Sodium-glucose cotransporter-2 (SGLT2) inhibitors. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm446852.htm. Updated May 16, 2017. Accessed October 27, 2017."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2696730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T12:32:26Z","timestamp":1536064346000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2018.3034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2018.3034","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733806817.793556285","asserted-by":"object"}]},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}